Literature DB >> 8458602

Rate-dependence of class III actions in the heart.

C Funck-Brentano1.   

Abstract

The pharmacodynamics of many antiarrhythmic drugs are altered by heart rate. The ability of sodium channel blockers to decrease conduction velocity (class I action) is more pronounced with rapid heart rates. Drugs with class III action increase action potential duration and refractoriness in the heart. Most drugs with class III actions, currently being developed, produce their action by blocking one or several of the potassium channels responsible for repolarization. In vitro and in vivo studies have shown that their ability to increase repolarization time is less pronounced, or even disappears, at rapid pacing or heart rates. This so called 'inverse' rate-dependence of class III action is a characteristic of all drugs currently used in man except amiodarone, for which prolongation of repolarization time persists to a limited extent with rapid heart rates. It has been suggested that one possible mechanism of the inverse rate-dependence of class III action is related to the preferential binding of drugs to the potassium channels in the closed, polarized state. An inverse rate-dependence of class III action has also been found on prolongation of refractoriness. However, preliminary studies suggest that the positive inotropism of class III drugs not only persists but may increase with rapid heart rates. The clinical consequences of this phenomenon remain unclear, especially in view of the fact that the rate-dependence of class III action on dispersion of repolarization has not been specifically studied and that class III actions tend to decrease in ischemic tissues. However, the increase of action prolongation at slow heart rates may contribute to the bradycardia-dependent development of torsades de pointes arrhythmias.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458602     DOI: 10.1111/j.1472-8206.1993.tb00217.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  3 in total

Review 1.  Antiarrhythmics--from cell to clinic: past, present, and future.

Authors:  J C Hancox; K C Patel; J V Jones
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

Review 2.  Dofetilide: a review of its use in atrial fibrillation and atrial flutter.

Authors:  K J McClellan; A Markham
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Regulation of A1 adenosine receptors by amiodarone and electrical stimulation in rat myocardial cells in vitro.

Authors:  D El-Ani; K A Jacobson; A Shainberg
Journal:  Biochem Pharmacol       Date:  1997-09-01       Impact factor: 5.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.